Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of Health Canada Patents covering Semaxanib.

Client Email

Product

Semaxanib
HEALTH CANADA PATENTS

Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Semaxanib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 NDC API

3 NDC API

FINISHED DOSAGE FORMULATIONS

21 FDF Dossiers, 1 FDA Orange Book, 13 Europe, 2 Canada, 4 Australia, 1 South Africa

21 FDF Dossiers
1 FDA Orange Book
13 Europe
2 Canada
4 Australia
1 South Africa

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 12 SPI Pharma, 1 Nanjing Well Pharmaceutical, 3 Pfanstiehl, 2 Actylis, 2 BASF, 3 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 2 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

1 Rochem International Inc
12 SPI Pharma
1 Nanjing Well Pharmaceutical
3 Pfanstiehl
2 Actylis
2 BASF
3 Gangwal Chemicals
1 Ingredion Pharma Solutions
2 Kerry
2 Microlex e.U
1 Pluviaendo
3 Roquette
2 Seppic
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 11 Taste Masking, 10 Chewable & Orodispersible Aids, 9 Parenteral, 9 Direct Compression, 4 Thickeners and Stabilizers, 4 Solubilizers, 3 Co-Processed Excipients, 3 Disintegrants & Superdisintegrants, 3 Granulation, 2 Surfactant & Foaming Agents, 2 Coating Systems & Additives, 2 Topical, 1 Emulsifying Agents, 1 API Stability Enhancers

17 Fillers, Diluents & Binders
11 Taste Masking
10 Chewable & Orodispersible Aids
9 Parenteral
9 Direct Compression
4 Thickeners and Stabilizers
4 Solubilizers
3 Co-Processed Excipients
3 Disintegrants & Superdisintegrants
3 Granulation
2 Surfactant & Foaming Agents
2 Coating Systems & Additives
2 Topical
1 Emulsifying Agents
1 API Stability Enhancers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 3 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
3 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 9 Finished Drug Prices, 7 Annual Reports

1 US Medicaid Prescriptions
9 Finished Drug Prices
7 Annual Reports

MARKET PLACE

2 APIs, 3 FDF Dossiers

2 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2Amgen Canada Inc.

filter Patent Reset all filters

2 All

01 22346996

filter Product Reset all filters

2 All

01 2ROMIPLOSTIM

filter Dosage Reset all filters

2 All

01 2POWDER FOR SOLUTION

filter Exp Date Reset all filters

2 All

01 22019-10-22

Product Main Page

01

Amgen Canada Inc.

Semaxanib

AAPS 2024

Not Confirmed

Amgen Canada Inc.

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-10-22

Date Granted : 2013-11-19

Brand Name : NPLATE

Patent Number : 2346996

Filing Date : 1999-10-22

Strength per Unit : 250 ?g / 0.5 mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2019-10-22

Date Granted : 2013-11-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Amgen Canada Inc.

Semaxanib

AAPS 2024

Not Confirmed

Amgen Canada Inc.

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-10-22

Date Granted : 2013-11-19

Brand Name : NPLATE

Patent Number : 2346996

Filing Date : 1999-10-22

Strength per Unit : 500 ?g / 1 mL

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2019-10-22

Date Granted : 2013-11-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?